BIAL Biotech is a center of excellence for the development of genetically-defined Parkinson’s disease therapeutics located in the heart of the Boston biotech cluster.  BIAL Biotech is a wholly owned subsidiary of BIAL.

We are dedicated to innovative, research and development in the field of neurodegeneration.

Our lead program builds on the genetic association between Parkinson’s disease (PD) and the GBA1 gene. BIAL Biotech team has extensive experience in drug discovery and development, focused on genetic and neurodegenerative diseases. Our team is highly motivated to make a real difference as soon as possible for patients with severe neurodegenerative and neurodevelopmental disease.

Management Team

Kees Been

Kees Been was formerly the President and CEO of EnVivo Pharmaceuticals; He led EnVivo for eight years from an early-stage start-up to a respected CNS company with a broad pipeline of NCE drug compounds, its lead compound in a phase 3 program for Alzheimer’s disease and schizophrenia. He spent four years at Biogen where he directed the Oncology Business Unit which was sold to Idec, and, as Senior Vice President of Business Development.

Peter Lansbury, PhD

Peter Lansbury manages the company’s research activities. He also retains his position as a professor of neurology at Harvard Medical School. Previously, Peter was Founder and Chief Scientific Officer of Link Medicine until it was acquired by AstraZeneca in 2012. Peter served as a Director of the Morris K. Udall Research Center of Excellence in Parkinson's Disease at Brigham and Women's Hospital. Peter received his doctorate from Harvard University, where he worked for Nobel laureate E. J. Corey.